Loading...
NTLA
XNAS
Market cap1.40bUSD
Nov 20, Last price  
10.00USD
1D
5.04%
1Q
-22.12%
Jan 2017
-23.72%
IPO
-58.33%
Name

Intellia Therapeutics Inc

Chart & performance

D1W1MN
XNAS:NTLA chart
P/E
—
P/S
20.74
EPS
—
Vol. 1Y
75.27%
Shs. 5Y
14.12%
Rev. 5Y
3.13%
Div Yld LY
—
Div Yld TTM
—
Revenues
68m
+16.92%
06,044,00016,479,00026,117,00030,434,00043,103,00057,994,00033,053,00052,121,00036,275,00057,877,00067,671,000
Net income
-413m
L-20.49%
-14,308,500-12,397,000-31,634,000-67,543,000-85,343,000-99,533,000-134,231,000-267,892,000-474,186,000-481,192,000-519,021,000-412,694,000
CFO
-349m
L-0.00%
-3,483,000-1,763,00036,109,000-65,276,000-61,257,000-103,240,000-49,912,000-225,030,000-333,287,000-394,086,000-348,880,000-348,880,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema. Additionally, Intellia is developing various other liver-focused therapies for conditions such as hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo (processed outside the body) pipeline features NTLA-5001, a candidate for acute myeloid leukemia. The company is also progressing proprietary programs focused on creating engineered cell therapies to address diverse oncological and autoimmune disorders. At the core of Intellia's technology is the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has established multiple licensing and collaboration agreements. These include a partnership with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for treating sickle cell disease, and a co-development agreement with Regeneron Pharmaceuticals, Inc. for potential products against hemophilia A and B. The company also collaborates with Ospedale San Raffaele and holds a strategic alliance with SparingVision SAS to develop novel genomic medicines for ocular diseases, leveraging CRISPR/Cas9 technology. The company, initially known as AZRN, Inc., was founded in 2014 and operates from its headquarters in Cambridge, Massachusetts.

Key people

Independent Chairman of the Board · since 2020
President, Chief Executive Officer, Director · since 2018
Thomas Barnes
Co-Founder and Chief Scientific Officer
Eliana Clark
Executive Vice President, Chief Technology Officer · since 2022
Birgit Schultes
Executive Vice President, Chief Scientific Officer · since 2025
Michael Dube
Chief Accounting Officer, Vice President · since 2024
Edward Dulac
Chief Financial Officer, Executive Vice President, Treasurer and Principal Financial Officer · since 2024
James Basta
Executive Vice President, General Counsel, Corporate Secretary · since 2021
Independent Director · since 2022
William Chase
Independent Director · since 2023
Independent Director · since 2019
Independent Director · since 2024
Jesse Goodman
Independent Director · since 2018
Independent Director · since 2021
IPO date
May 06, 2016
Employees
598
Domiciled in
US
Incorporated in
US
Legal address
c/o THE CORPORATION TRUST COMPANY, CORPORATION TRUST CENTER, 1209 ORANGE ST
WILMINGTON, DE 19801
US
Headquarters
130 Brookline Street; Suite 201
Cambridge, MA 02139
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT